Skip to Main Content

Paper Details

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.
J Clin Oncol
102
2020
APOBEC, ATM, KRAS, MM, MYC, NRAS single nucleotide variants, Patients, SMM, SNVs, Smoldering Multiple Myeloma, Smoldering multiple myeloma, TP53, deletion 17p, genomic, mitogen-activated protein kinase, monoclonal gammopathy, multiple myeloma, patients, tumors
Author NameAffiliation
Jihye ParkDana-Farber Cancer Institute, Harvard Medical School
Jihye ParkBroad Institute of MIT and Harvard
Jihye ParkDana-Farber Cancer Institute, Harvard Medical School
Jihye ParkBroad Institute of MIT and Harvard
Shankara AnandBroad Institute of MIT and Harvard
Amaro Taylor-WeinerBroad Institute of MIT and Harvard
Eliezer M Van AllenDana-Farber Cancer Institute, Harvard Medical School
Eliezer M Van AllenBroad Institute of MIT and Harvard
Eliezer M Van AllenDana-Farber Cancer Institute, Harvard Medical School
Eliezer M Van AllenBroad Institute of MIT and Harvard
Ignaty LeshchinerBroad Institute of MIT and Harvard
Kenneth C AndersonDana-Farber Cancer Institute, Harvard Medical School
Kenneth C AndersonDana-Farber Cancer Institute, Harvard Medical School
François AguetBroad Institute of MIT and Harvard
Chip StewartBroad Institute of MIT and Harvard
Chip StewartBroad Institute of MIT and Harvard
Peter Leif BergsagelMayo Clinic
Gad GetzBroad Institute of MIT and Harvard
Gad GetzMassachusetts General Hospital, Harvard Medical School
Gad GetzBroad Institute of MIT and Harvard
Gad GetzMassachusetts General Hospital, Harvard Medical School
  • 1 - 21

Datasets

Release 1.2